Evidence map›Paper›PMID 37207159›Full record

ArticleFrontiers in oncology2023

Liquid biopsy can cure early colorectal cancer recurrence - Case Report.

Alexander Baraniskin, Hideo A Baba, Dirk Theegarten, Thomas Mika, Roland Schroers, Susanne Klein-Scory

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander BaraniskinDepartment of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.
Hideo A BabaInstitute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Dirk TheegartenInstitute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Thomas MikaDepartment of Medicine, Hematology and Oncology, University Hospital Knappschaftskrankenhaus Bochum GmbH, Ruhr University of Bochum, Bochum, Germany.
Roland SchroersDepartment of Medicine, Hematology and Oncology, University Hospital Knappschaftskrankenhaus Bochum GmbH, Ruhr University of Bochum, Bochum, Germany.
Susanne Klein-ScoryDepartment of Medicine, Hematology and Oncology, University Hospital Knappschaftskrankenhaus Bochum GmbH, Ruhr University of Bochum, Bochum, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the context of colorectal cancer (CRC), circulating tumor DNA (ctDNA) is frequently used to monitor the minimal residual disease (MRD). ctDNA has become an excellent biomarker to predict which patients with CRC are likely to relapse due to the persistence of micrometastases. MRD diagnosis

Indexed as

colorectal cancerddPCRfollow-upliquid biopsymutation detectionPET-CTRastumor promotor P53 TP53

Identifiers

PMID37207159
PMCPMC10188995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.